2026-08-25T13:23:16-07:00 2025-12-31 680260103 REGALIA BERGER & BERGER CPAS 103 TOWN COUNTRY DR STE K DANVILLE CA 94526 990 2025-01-01 651230251 THE CANARY FUND DBA CANARY FOUNDATION CANA 6506463200 PO Box 620134 Woodside CA 94062 Don Listwin Founder & CEO 6506463200 2026-08-25 true Douglas W Regalia P00186389 9253140390 2025 2025-03-06 01:10:19Z Don Listwin PO Box 620134 Woodside CA 940629991 2205595 false X www.canaryfoundation.org X 2004 CA Canary Foundation is the world's first non-profit organization dedicated solely to the funding, discovery and development of tests for early cancer detection. 5 5 3 0 1755058 2163219 0 37758 42376 0 1792816 2205595 1291597 1760069 0 265250 297850 0 70519 170166 127498 1727013 2185417 65803 20178 1850228 2450031 115382 707828 1734846 1742203 X Canary Foundation is a public charity exempt from U.S. federal income tax under Section 501(c)(3) of the Internal Revenue Code in the United States. Canary Foundation of Canada is a Public Foundation registered with the Canada Revenue Agency; Business Number 82906 8550 RROOO1.The Canary Foundation has assembled teams of cancer researchers recognized by their peers as leaders in their disciplines from across multiple institutions and disciplines to attack the problem of early detection in a new, collaborative, action-oriented manner with the foremost objective of translating research into clinical applications. Canary differentiators include: * Dedication to early detection * Leaders in collaborative science * Focused and managed research * Best-in-class talent * 100% of donations goes to researchOne of the first decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers pro false false 2011373 1760069 The goal of the Canary Scientific Programs is to develop blood tests and imaging tests that can together be used to detect lethal cancers at a curable stage. Our plan for early and accurate cancer detection involves first screening patients with a blood test and then moving those patients who tested positive to a high-resolution imaging test to further isolate cancer so that it can be removed. Chances of survival are highest when cancer is detected before it spreads. Thus, accurate detection of cancer that would otherwise be lethal at its earliest stage promises to dramatically improve survival after diagnosis. Canary has supported research programs focused on solid tumor cancer types including ovarian, lung, pancreas and prostate cancers, as well as a Collaborations Program with collaborating early detection programs and centers that include the Canary Center at Stanford for Cancer Early Detection. Canary Ovarian Cancer Program: The goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. The program focuses on high grade serous ovarian cancer, which is the most common and lethal subtype, in order to have the highest impact on reducing ovarian cancer mortality. Our aims include understanding the earliest stages of cancer development in the fallopian tube, identifying molecular markers for early detection or prevention, and developing advanced imaging techniques for early detection of the disease. Development of blood and imaging tests follows a similar roadmap; both include biomarker discovery followed by validation, but they also involve different techniques and challenges. Canary Lung Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed. The Canary Lung Cancer Program has supported the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening.(continued Sch O) Canary Prostate Cancer Program:The specific goals of the Canary Foundation Prostate program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but invalidated candidate markers for prostate cancer, we are focusing our initial efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on their ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We are considering both fluid-based and tissue-based biomarkers for prognostic applications. The Canary Prostate Active Surveillance Study (PASS) enrolls men who opt for active surveillance of their early stage prostate cancer. Men are followed closely for signs of cancer progression, donating biospecimens and clinical data for a minimum of 5 years or until receiving treatment for their disease. The biospecimens and clinical data provide a valuable resource to test promising biomarkers and predictive tools for their use in the active surveillance setting.Canary Pancreatic Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal pancreatic cancers at an early stage when they can be cured through surgical resection. We anticipate that no single biomarker will be sufficient to create a test with the required sensitivity and specificity to detect pancreatic cancer early. Instead, a definitive diagnosis will rely upon combinations of biomarkers and upon blood and imaging tests used together. To this end, the Canary pancreatic cancer researchers have collaborated to discover and validate biomarkers that will provide the basis for blood and imaging tests for the early detection of pancreatic cancer. Canary Collaborations Program:Canary Foundation believes that a collaborative, coordinated approach is necessary to achieve our goals. Our multi-disciplinary, multi-institutional Early Detection Program provides a great example of this philosophy in action. Our foundation partnerships link mutual scientific expertise and entrepreneurial spirit in the hopes of advancing research in the diagnostic arena of early cancer detection. We partner with research institutions, foundations, industry and government organizations. Collaborating programs include the Canary Center at Stanford and the CRUK Cambridge Centre Early Detection Programme at the University of Cambridge in England. We provide scientific program management to make sure that all funded research activities among the scientists and clinicians at the various partner institutions are on track and that any obstacles are rapidly addressed and overcome. 2011373 true true false false false false false false false false true false false true false true true false false false true true false false false false false true false true false false false false false false false false true false false false false false false false false true 5 0 true 3 true false false false false true true false false 0 false false false false false false false X 5 5 true false false false false false false true true false false true true true true true true true true false CA X X Candy Gularte-Finance Mgr 6506463200 PO Box 620134 Woodside CA 940629991 X Heidi Auman Program Manager 40.00 0.00 201750 0 0 Don Listwin Founder & CEO 8.00 0.00 X X 0 0 0 Kevin Kennedy Treasurer 4.00 0.00 X X 0 0 0 Michael Ball Director 4.00 0.00 X 0 0 0 Dale Jantzen Director 4.00 0.00 X 0 0 0 Hilary Valentine Director 4.00 0.00 X 0 0 0 201750 1 false true false 0 2163219 48821 2163219 0 42376 42376 0 0 0 0 0 0 0 0 2205595 42376 1748069 1748069 0 12000 12000 0 0 0 174975 118520 49497 6958 29851 20220 8444 1187 0 93024 63010 26314 3700 0 0 0 0 0 0 7445 7445 0 6296 950 5346 0 0 0 0 0 36453 36453 0 0 12326 12151 175 4549 4549 Event & Fundraising Activities 58674 58674 Bank and merchant fees 1755 1755 0 2185417 2011373 103525 70519 461079 192765 1231651 1331495 125000 583333 0 0 0 0 0 0 78450 56525 32498 21925 0 0 0 0 320513 1850228 2450031 115382 707828 115382 707828 X 1609846 838357 125000 903846 1734846 1742203 1850228 2450031 X 20178 -12821 X X false true X true false X 834065 2494411 1858743 1755058 2212040 9154317 0 0 834065 2494411 1858743 1755058 2212040 9154317 4946485 4207832 -126 70 24569 37758 48821 111092 0 0 9265409 0.45410 0.56020 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 59299 38952 20347 19151 17573 1578 21925 Grants and pledges receivable-long-term 320513 320513 X 1413928 125000 125000 1288928 916667 916667 2205595 2185417 2185417 2185417 Part X : FIN48 Footnote Income Taxes The Fund is organized as California nonprofit corporation and has been recognized by the IRS as exempt from federal income taxes under IRC Section 501(a) as organizations described in IRC Section 501(c)(3), qualify for the charitable contribution deduction under IRC Sections 170(b)(1)(A)(vi) and (viii), and has been determined not to be private foundations under IRC Sections 509(a)(1) and (3), respectively. The Fund is annually required to file a Return of Organization Exempt from Income Tax (Form 990) with the IRS. The Fund is not required to file an Exempt Organization Business Income Tax Return (Form 990-T) because it had no unrelated business taxable income for the year ended December 31, 2025.The Fund has received notification from the Internal Revenue Service and the State of California that it qualifies for tax-exempt status under Section 501(c)(3) of the Internal Revenue Code and Section 23701d of the California Revenue and Taxation Code. The exemptions are subject to periodic review by the federal and state taxing authorities and management is confident that the Fund continues to satisfy all federal and state statutes in order to qualify for continued tax exemption status. Part XI, Line 2d: Other revenue amounts included in F/S but not included on form 990 Net assets released from restrictions $125000 Part XI, Line 4b: Other revenue amounts included on 990 but not included in F/S Restricted contributions $916667 true Canada 0 0 Funding of Cancer Research Grant 12000 12000 12000 Canada Cancer Research 12000 Wire Transfr 1 false false false false false false Part II, Line 1 - Method of Accounting Accrual Basis Method of Accounting true Beth Israel Deaconess Medical 330 Brookline Avenue Boston MA 02215 042103881 42000 0 Cancer Research Providence Swedish Cancer Ins 1221 E Madison Street Seattle WA 98104 910433740 501(c)(3) 174400 0 Seattle Inst Biomedical Clinical 1660 S Columbian Way S-151F Seattle WA 98108 911452438 501(c)(3) 50000 0 Cancer Research Stanford School Of Medicine 3155 Porter Drive Palo Alto CA 94304 946174066 209000 0 Cancer Research Stanford University Fdtn 300 Pasteur Drive Stanford CA 97305 946174066 35067 0 Sanjiv Sam Gambhir Professorship UC San Diego Foundation 9500 Gilman Drive La Jolla CA 92093 952872494 501(c)(3) 450000 0 Cancer Research UCSF Foundation 500 Parnassus MU-200W Box 0244 San Francisco CA 94143 942829914 501(c)(3) 12000 0 Cancer Research University of Michigan 648 N Shaw Lane Room East Lansing MI 48824 381358000 203950 0 Cancer Research University of Pennsylvania 3620 Hamilton Walk Philadelphia PA 19104 231352685 353394 0 Cancer Research University of Texas Health Ct 7703 Floyd Curl Drive San Antonio CA 78229 237232618 50000 0 Cancer Research University of Washington 1959 NE Pacific Seattle WA 98195 943079432 118258 0 Cancer Research Urology of Virginia 225 Clearfield Avenue Virginia Beach VA 23462 510236428 50000 0 Cancer Research 12 0 Grantmaker's Description of How Grants are Used The Canary Fund requires ongoing feedback in the form or oral and written reports in order to monitor the progress of each grant funded for approval. X X X X false false false false false false false false false Heidi Auman Program Manager 201750 201750 X 1 48821 FMV false false false Form 990, Part VI, Section A, Line 1a In accordance with common practice in the nonprofit community, the Board delegates certain matters to The Executive Committee, which is empowered to act between board meetings if necessary, and sometimes with specifically delegated authority to act in particular areas on behalf of the full board. Form 990, Part VI, Section A, Line 2 Board members Don Listwin (President) and Hilary Valentine (Director) are related to each other as husband and wife. Board member Don Listwin sits on the Board of directors of fellow board member Michael Ball's company. Form 990, Part VI, Section B, Line 11b Form 990 is prepared by an outside tax professional. The form is then reviewed by the organization's management. After a full review, the final version of the tax return is provided to all members of the organization's voting body. A representative of management authorizes the final form 990 which is then e-filed with the internal revenue service. Form 990, Part VI, Section B, Line 12c Members of the Board of Directors review all potential conflicts of interest periodically. Top management and all Board members are required to disclose potential conflicts and any related party affiliations. The organization seeks full transparency on all relationships. Any potential conflicts (in fact or appearance) are discussed openly and resolved in accordance with the organization's policies and procedures. Form 990, Part VI, Section B, Line 15a Members of the board of directors review the compensation of all high-level personnel periodically in accordance with IRS rules and regulations. Efforts are made to secure compensation data from industry sources in order to determine competitiveness and appropriateness of salaries. Every effort is made to ensure that the process is thorough and transparent in accordance with IRS guidelines and the organization's policies and procedures. Form 990, Part VI, Section B, Line 15b Compensation of other personnel and highly compensated employees is reviewed periodically by members of management. Efforts are made to secure compensation data from industry sources in order to determine competitiveness and appropriateness of salaries and all related benefits. All decisions are then documented in personnel files. Form 990, Part VI, Section C, Line 18 Tax returns are available for download from several websites and by request from the organization's office in Woodside California. Form 990, Part VI, Section C, Line 19 All of the organization's governing documents, financial statements, and other legal filings are maintained in a secure environment and held available for inspection by tax authorities and the general public. Tax returns are posted annually to our website and to www.guidestar.org (where they are available for viewing as electronic copies) and are also available by request from the organization's office. Form 990, Part XI, Line 9 Change in value of long-term pledges receivable = -$12821 Form 990, Part XII, Line 2c Under the California Nonprofit Integrity Act, an exempt organization with annual revenue of $2 million or more is required to have an Audit Committee to select an audit Firm, review the audit, and approve the audit of its annual financial statements. The audited financial statements are prepared by a qualified and licensed independent audit firm. The audit report is reviewed and approved by the organization's management and the Board of Directors.